Newer antiepileptic drugs in the management of agitation/aggression in patients with dementia or developmental disability

The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists
David R P Guay

Abstract

To assess the potential role of newer antiepileptic drugs (AEDs) in the management of agitation/aggression in patients with dementia or developmental disability. A MEDLINE/PUBMED search (1986-May 2007) was conducted to identify pertinent English language studies of six newer AEDs, as well as carbamazepine and valproate, in the management of agitation/aggression. All studies evaluating any aspect of management of agitation/aggression, emphasizing those associated with dementia or developmental disability. Pharmacotherapy of agitation/aggression in these two patient groups remains an underexplored area. Carbamazepine and valproate have a reasonable, readily available evidence base, and preliminary recommendations regarding their use in these two patient groups. The most published data with newer AEDs involve gabapentin, followed by topiramate. Even so, the literature regarding newer AEDs is modest in volume. Based on current data, gabapentin, oxcarbazepine, and topiramate are qualitatively similar in efficacy to carbamazepine/valproate in the management of agitation/aggression. However, studies-to-date in this field have had, in the main, numerous design flaws. In considering use of newer AEDs, the clinician needs to be aware of ...Continue Reading

References

Sep 1, 1992·Journal of the American Geriatrics Society·C M MazureJ S Cellar
Aug 1, 1992·The British Journal of Psychiatry : the Journal of Mental Science·J Lewin, D Sumners
Sep 1, 1992·The Journal of Nervous and Mental Disease·J A Mattes
Jan 1, 1990·The Journal of Neuropsychiatry and Clinical Neurosciences·J A Mattes
Dec 1, 1989·The American Journal of Psychiatry·E S Garza-TreviñoW F Alexander
Jun 1, 1989·The American Journal of Psychiatry·D B Marin, B S Greenwald
Jan 1, 1989·Progress in Neuro-psychopharmacology & Biological Psychiatry·H G FosterC C Chi
Aug 1, 1988·Acta Psychiatrica Scandinavica·L N Yatham, P A McHale
Jan 1, 1988·Journal of Geriatric Psychiatry and Neurology·J F Patterson
Jan 1, 1988·Psychosomatics·G B Leong, J A Silva
Apr 1, 1986·The American Journal of Psychiatry·D L Gardner, R W Cowdry
Nov 1, 1973·Comprehensive Psychiatry·L A GottschalkD E Bates
Jun 12, 1982·Lancet·H P Hakola, V A Laulumaa
Nov 17, 1984·Lancet·J A Mattes
Apr 1, 1984·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·P C Hoaken
Nov 1, 1983·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·R Yassa, D Dupont
Jan 1, 1995·The Journal of Neuropsychiatry and Clinical Neurosciences·A D LottM A Keys
Dec 1, 1994·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·J M de la Fuente, F Lotstra
Mar 1, 1994·Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists·J Wilcox
Aug 1, 1994·Journal of the American Geriatrics Society·R C SivalJ F van Nieuwkerk
Oct 1, 1993·Journal of Geriatric Psychiatry and Neurology·A M MellowS Davis
Jan 1, 1996·Epilepsia·D O LeeM A Mikati
Jun 1, 1996·The Journal of Pediatrics·D S KhuranaM A Mikati
Jan 1, 1996·The Journal of Neuropsychiatry and Clinical Neurosciences·P E Chatham-Showalter
Apr 1, 1996·Journal of the American Academy of Child and Adolescent Psychiatry·J E CuevaM Campbell
Feb 1, 1997·Journal of Clinical Psychopharmacology·W M Regan, S M Gordon
Jan 1, 1997·The Journal of Clinical Psychiatry·S J DonovanD F Klein
Jan 1, 1996·Journal of Child and Adolescent Psychopharmacology·P A Davanzo, B H King
Oct 8, 1997·Journal of Clinical Psychopharmacology·E S BarrattT A Kent
Jan 20, 1998·The American Journal of Psychiatry·P N TariotC Irvine
Mar 7, 1998·International Journal of Geriatric Psychiatry·M E KunikR H Workman
Mar 12, 1998·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·N Herrmann
Aug 26, 1998·The Journal of Neuropsychiatry and Clinical Neurosciences·D M HiltyR E Hales
Sep 18, 1998·Drugs & Aging·G GoldenbergS Rangu
Jan 28, 1999·The Journal of Clinical Psychiatry·R J Kavoussi, E F Coccaro
Jun 4, 1999·Journal of Pain and Symptom Management·L C StirlingA Tookman
Jun 17, 1999·Pediatric Neurology·J McManaman, D A Tam
Oct 3, 1999·Journal of Clinical Psychopharmacology·R A Low, M Brandes
Feb 1, 2000·Journal of Clinical Psychopharmacology·N HerrmannM Myszak
Mar 4, 2000·The Journal of Neuropsychiatry and Clinical Neurosciences·D M RoaneR N Rosenthal
Jun 30, 2000·The American Journal of Psychiatry·S Devarajan, S M Dursun
Apr 17, 2001·The Annals of Pharmacotherapy·L J Miller

❮ Previous
Next ❯

Citations

Jun 18, 2009·Clinical Practice and Epidemiology in Mental Health : CP & EMH·Benedikt AmannHarald Hampel
Jun 28, 2012·Drugs & Aging·Christian R Dolder, Kimberly L Nealy
Sep 28, 2010·Indian Journal of Pharmacology·Bindu Susan VargheseSaleh Bin Mohammed Al Khusaiby
Mar 29, 2012·The Kaohsiung Journal of Medical Sciences·Yi-Chun Yeh, Wen-Chen Ouyang
Nov 17, 2010·Neuroscience Research·María José G M PiedrasCarmen Cavada
Nov 19, 2011·Journal of Pharmacy Practice·Christian R DolderJonathan McKinsey
Dec 24, 2018·British Journal of Clinical Pharmacology·Thitiporn SupasitthumrongSimon J C Davies

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved